蔡其明

    上海市奉贤区中心医院药剂科，上海 201400

    血管内皮生长因子抑制剂治疗晚期胃癌的Meta分析

    蔡其明

    上海市奉贤区中心医院药剂科，上海201400

    目的研究血管内皮生长因子(VEGF)抑制剂治疗晚期胃癌的效果与安全性。 方法通过检索1990年1月～2015年8月PubMed、EMBASE、Cochrane Centra1 Register of Contro11ed Tria1s、MEDLINE和中国知网等电子数据库，并用Stata 12.0软件对其进行VEGF抑制剂治疗晚期胃癌的随机对照试验研究的Meta分析。结果纳入7个试验包括2340例患者。与无VEGF抑制剂治疗比较，VEGF抑制剂治疗可以显著改善总生存期(HR=0.71，95%CI：0.54～0.88，P=0.003)、无进展生存期(HR=0.57，95%CI：0.38～0.77，P<0.001)、总缓解率(RR=1.29，95%CI：1.11～1.47，P<0.001)；VEGF抑制剂治疗可能发生更多3级以上不良反应。结论VEGF抑制剂治疗可显著改善晚期胃癌患者的总体生存，尤其是较早接受治疗的患者。

    晚期胃癌曰血管内皮生长因子抑制剂曰Meta分析

    [Abstract]Objective To study the effectiveness and security of vascu1ar endothe1ia1 growth factor(VEGF)inhibitors in the treatment of advanced gastric cancer.Methods The databases of PubMed，EMBASE，Cochrane Centra1 Register of Contro11ed Tria1s，MEDLINE and CNKI from January 1990 to August 2015 were searched.A Meta-ana1ysis of randomized contro11ed tria1s(RCTs)was performed to assess the efficacy and safety of VEGF inhibitors in the treatment of advanced gastric cancer by using Stata 12.0.Results Seven RCTs which invo1ved 2340 patients were u1timate1y enro11ed. Compared with the treatment without VEGF inhibitors ......